Clinical Trial Update: Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix [Phase 2]

View source ↗

Summary

A Phase 2 trial of Belotecan (CKD-602) in recurrent or progressive carcinoma of the cervix has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Belotecan (CKD-602) (Belotecan)

Snippet

Sponsor: Sokbom Kang | Conditions: Cervical Cancer | Phase 2 | Status: COMPLETED